"Prevention" and the goals of genetic medicine

Human Gene Therapy

Volumn 6, Issue 12, 1995, Pages 1595-1605

  Juengst, Eric T ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIET; DISEASE TRANSMISSION; GENE THERAPY; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN CELL; MEDICAL ETHICS; NEWBORN SCREENING; PHENYLKETONURIA; PRENATAL DIAGNOSIS; PROPHYLAXIS; PUBLIC HEALTH; REVIEW;

ANALYTICAL APPROACH; AUTONOMY; CARRIERS; CLINICAL APPROACH/SOURCE; FUTURE GENERATIONS; GENETIC DISORDERS; GENETIC SERVICES; GENETICS AND REPRODUCTION; MORAL POLICY; RISKS AND BENEFITS; SELECTIVE ABORTION; STIGMATIZATION;

ETHICS, MEDICAL; GENE THERAPY; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETIC SERVICES; GENETICS, MEDICAL; GENOTYPE; GERM CELLS; HUMANS; PERSONAL AUTONOMY; PHENOTYPE; RISK ASSESSMENT; SOCIAL RESPONSIBILITY; SOCIOLOGY;

EID: 0029614761     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1995.6.12-1595     Document Type: Article

References (59)

1. ALLEN, G.E. (1989). Eugenics and American social history, 1880-1950. Genome 31, 885-889.
2. BARTELS, D., LEROY, B., and CAPLAN, A. (eds.) (1993). Prescribing Our Future: Ethical Challenges in Genetic Counseling. (deGruyter, Hawthorne, NY).
3. BENJAMIN, C.M., ADAM, S., WIGGINS, S., THEILMANN, J.L., COPLEY, T.T., BLOCH, M., et al. (1994). Proceed with care: Direct predictive testing for Huntington's Disease. Am. J. Hum. Gen. 55, 606-617.
4. BLITZER, M.G., and McDOWELL, G.A. (1992). Tay-Sachs Disease as a model for screening in-born errors. Clin. Lab. Med. 12, 463-480.
5. BOTKIN, J. (1990). Prenatal screening: Professional standards and the limits of parental choice. Obstetr. Gynecol. 75, 875-880.
6. CAO, A., ROSATELLI, M.C., and GALANELLO, R. (1991). Population-based genetic screening. Curr. Opin. Genet. Dev. 1, 48-53.
7. CAPLAN, A. (1992). If gene therapy is the cure, what is the disease? In Gene Mapping: Using Law and Ethics as Guides. S. Elias and G. Annas, eds. (Oxford University Press, New York) pp. 128-142.
8. CAPRON, A. (1979). Autonomy, confidentiality and quality care in genetic counseling. In Genetic Counseling: facts, Values and Norms. A. Capron et al., eds. (Alan R. Liss, New York) pp. 334.
9. CASKEY, T. (1993). Molecular medicine: A spin-off from the helix. J. Am. Med. Assn. 269, 1986-1992.
10. CHAPPELE, J.C., DALE, R., and EVANS, B.C. (1987). The new genetics: Will it pay its way? Lancet i, 1189-1192.
11. C.I.O.M.S. (1992). The Declaration of Inuyama and Report of a Working Group on Human Gene Therapy. Law, Medicine and Health Care 20, 35-37.
12. CLARKE, A. (1990). Genetics, ethics and audit. Lancet 335, 1145-1147.
13. COUNCIL FOR RESPONSIBLE GENETICS. (1993). Position statement on human germ-line manipulation. Hum. Gene Ther. 4, 35-39.
14. COUNCIL OF REGIONAL NETWORKS FOR GENETIC SERVICES. (1994). Code of Ethical Principles for Genetics Professionals, Cornell University Medical College, Cornell, New York.
15. DANKS, D. (1994). Germ-line gene therapy: No place in treatment of genetic disease. Hum. Gene Ther. 5, 151-152.
16. DAVIS, B. (1992). Germ-line therapy: Evolutionary and moral considerations. Hum. Gene Ther. 3, 361-365.
17. ELIAS, S., and ANNAS, G. (1992). Somatic and germ-line gene therapy. In Gene Mapping: Using Law and Ethics and Guides. G. Annas and S. Elias, eds. (Oxford U. Press, New York) pp. 142-157.
18. FASTEN, N. (1935). Principles of Genetics and Eugenics. (Ginn and Co., New York).
19. FADEN, R. (1994). Reproductive genetic testing, prevention and the ethics of mothering. In Women and Prenatal Testing: Facing the Challenges of Genetic Technology. E. Thomson and K. Rothenberg, eds. (Ohio State Univ. Press, Columbus, OH) pp. 88-98.
20. FINE, M., and ASCH, A., eds. (1988). Women with Disabilities: Essays in Psychology, Culture and Politics. (Temple University Press, Philadelphia).
21. FLETCHER, J. (1990). Evolution of ethical debate about human gene therapy. Hum. Gene Ther. 1, 55-69.
22. FLETCHER, J., and ANDERSON, W.F. (1992). Germ-line germ therapy: A new stage of debate. Law, Medicine and Health Care 20, 26-39.
23. FOWLER, G., JUENGST, E., and ZIMMERMAN, B. (1989). Germline gene therapy and the clinical ethos of medical genetics. Theoret. Med. 10, 151-165.
24. HOLTZMAN, N.A. (1989). Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era. (The Johns Hopkins University Press, Baltimore, MD).
25. HUBBARD, R. (1986). Eugenics and prenatal testing. Int. J. Health Services 16, 227-242.
26. JUENGST, E. (1988). Prenatal diagnosis and the ethics of uncertainty. In Medical Ethics: A Guide for Health Professionals. J. Monagle and D. Thomasma, eds. (Aspen Pub. Co, Rockville, MD) pp. 12-25.
27. JUENGST, E. (1989). Patterns of reasoning in medical genetics. Theoret. Med. 10, 101-105.
28. KAPLAN, D. (1994). Prenatal screening and diagnosis: The impact on persons with disabilities. In Woman and Prenatal Testing: Facing the Challenges of Genetic Technology. K. Rothenberg and E. Thomson, eds. (Ohio State University Press, Columbus, OH) pp. 49-67.
29. KENAN, R., and SCHMIDT, R. (1987). Social implications of screening programs for carrier status: Genetic diseases in the 1970's and AIDS in the 1980's. In Dominant Issues in Medical Sociology, 2nd ed. H Schwartz, ed. (Random House, New York).
30. KESSLER, S. (1980). The psychological paradigm shift in genetic counseling. Social Biol. 27, 67-85.
31. KEVLES, D. (1985). In the Name of Eugenics: Genetics and the Uses of Human Heredity. (Knopf, New York).
32. LAPPE, M. (1991). Ethical issues in manipulating the human germ line. J. Med. Philos. 16, 621-641.
33. LAST, J.M. (1986). Scope and Methods of Prevention. In Public Health and Preventive Medicine, 12th ed. J. Last, ed. (Appleton-Century-Crofts, Norwalk, CT) pp. 3-10.
34. MARKEL, H. (1992). The stigma of disease: Implications for carrier screening. Am. J. Med. 93, 209-215.
35. MULLER-HILL, B. (1988). Murderous Science: Elimination by Scientific Selection of Jews, Gypsies, and Others, Germany 1933-1945. (Oxford University Press, New York).
36. MUNSON, R., and DAVIS, L. (1992). Germ-line gene therapy and the medical imperative. Kennedy Institute of Ethics Journal 2, 137-158.
37. NATIONAL SOCIETY OF GENETIC COUNSELORS. (1992). Code of Ethics. J. Genet. Counsel. 1, 41-42.
38. NEEL, J.V. (1993). Germ-line gene therapy: Another view. Human Gene Ther. 4, 127-128.
39. PALOMAKI, G.E. (1994). Population based prenatal screening for the fragile X syndrome. J. Med. Screening 1, 65-72.
40. PAUL, D. (1984). Eugenics and the left. J. History Ideas 45, 567-590.
41. PEMBREY, M. (1984). Do we need gene therapy? Nature 311, 200.
42. PORTER, I. (1982). The control of hereditary disorders. Annu. Rev. Pub. Health 3, 277-319.
43. PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL AND BEHAVIORAL RESEARCH. (1983). Screening and Counseling for Genetic Conditions. (U.S. Government Printing Office, Washington, DC).
44. REED, S. (1955). Counseling in Medical Genetics. (W.B. Saunders Co., New York).
45. REILLY, P. (1991). The Surgical Solution: A History of Involuntary Sterilization in the U.S. (The Johns Hopkins University Press, Baltimore, MD).
46. SAXTON, M. (1988). Prenatal screening and discriminatory attitudes about disability. In Embryos, Ethics and Women's Rights. E. Baruch, A. D'Adamo, and J. Seager, eds. (Haworth Press, New York).
47. SNYDER, L.H., and DAVID, P.R. (1965). Genetics and preventive medicine. In Preventive Medicine: An Epidemiological Approach, 3rd ed. H.R. Leavell, and E.C. Clark, eds. (McGraw-Hill, New York) pp. 321-345.
48. SORENSON, J. (1974). Biomedical innovation, uncertainty and doctor-patient interaction. J. Health Social Behav. 15, 366-374.
49. STROHMAN, R. (1993). Ancient genomes, wise bodies, unhealthy people: Limits of a genetic paradigm in biology and medicine. Persp. Biol. Med. 37, 112-145.
50. THOMSON, E., and ROTHENBERG, K. (1993). National Institutes of Health workshop statement on reproductive genetic testing: Impact on women. Am. J. Hum. Gen. 51, 1161-1163.
51. TSUI, L. (1992). The spectrum of cystic fibrosis mutations. Trends Genet. 8, 392-398.
52. WALTERS, L. (1991). Ethical issues in human gene therapy. J. Clin. Ethics 2, 267-274.
53. WALTERS, L. (1994). The ethics of human germ-line genetic intervention. In Genes and Human Self-Knowledge: Historical and Philosophical Reflections on Modern Genetics. R. Weir, S.C. Lawrence, and E. Fales, eds. (University of Iowa Press, Iowa City, IA) pp. 220-232.
54. WALTERS, L., and PALMER, J. (in press). The Ethics of Human Gene Therapy. (Oxford University Press, New York).
55. WARREN, M.A. (1985). Gendercide: The Implications of Sex Selection. (Rowan and Allanheld, Totowa, NJ).
56. WERTZ, D., and FLETCHER, J. (1989). Ethics and Human Genetics: A Cross-Cultural Perspective. (Springer-Verlag, Berlin).
57. WERTZ, D., FLETCHER, J., and BERG, K. (1995). Summary Statement on Ethical Issues in Medical Genetics: Report of WHO Temporary Advisers. WHO Document WHO/HDP/CONS/95, Geneva, Switzerland.
58. WIVEL, N.A., and WALTERS, L. (1993). Germ-line gene modification and disease prevention: Some medical and ethical perspectives. Science 262, 533-538.
59. ZIMMERMAN, B. (1991). Human germ-line therapy: The case for its development and use. J. Med. Philos. 16, 593-613.